318 related articles for article (PubMed ID: 32006396)
21. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (A). Mechanisms of interaction.
Ionov M; Lazniewska J; Dzmitruk V; Halets I; Loznikova S; Novopashina D; Apartsin E; Krasheninina O; Venyaminova A; Milowska K; Nowacka O; Gomez-Ramirez R; de la Mata FJ; Majoral JP; Shcharbin D; Bryszewska M
Int J Pharm; 2015 May; 485(1-2):261-9. PubMed ID: 25791760
[TBL] [Abstract][Full Text] [Related]
22. Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers.
Tang Y; Li YB; Wang B; Lin RY; van Dongen M; Zurcher DM; Gu XY; Banaszak Holl MM; Liu G; Qi R
Mol Pharm; 2012 Jun; 9(6):1812-21. PubMed ID: 22548294
[TBL] [Abstract][Full Text] [Related]
23. PAMAM versus PEI complexation for siRNA delivery: interaction with model lipid membranes and cellular uptake.
Chang PKC; Prestidge CA; Bremmell KE
Pharm Res; 2022 Jun; 39(6):1151-1163. PubMed ID: 35318566
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain.
Kim ID; Lim CM; Kim JB; Nam HY; Nam K; Kim SW; Park JS; Lee JK
J Control Release; 2010 Mar; 142(3):422-30. PubMed ID: 19944723
[TBL] [Abstract][Full Text] [Related]
25. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
26. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
27. Efficient and innocuous delivery of small interfering RNA to microglia using an amphiphilic dendrimer nanovector.
Ellert-Miklaszewska A; Ochocka N; Maleszewska M; Ding L; Laurini E; Jiang Y; Roura AJ; Giorgio S; Gielniewski B; Pricl S; Peng L; Kaminska B
Nanomedicine (Lond); 2019 Sep; 14(18):2441-2458. PubMed ID: 31456476
[No Abstract] [Full Text] [Related]
28. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.
Liu XX; Rocchi P; Qu FQ; Zheng SQ; Liang ZC; Gleave M; Iovanna J; Peng L
ChemMedChem; 2009 Aug; 4(8):1302-10. PubMed ID: 19533723
[TBL] [Abstract][Full Text] [Related]
29. SiRNA delivery systems based on neutral cross-linked dendrimers.
Liu J; Zhou J; Luo Y
Bioconjug Chem; 2012 Feb; 23(2):174-83. PubMed ID: 22292572
[TBL] [Abstract][Full Text] [Related]
30. siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector.
Tekade RK; Maheshwari RG; Sharma PA; Tekade M; Chauhan AS
Curr Pharm Des; 2015; 21(31):4614-36. PubMed ID: 26486147
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy.
Tarach P; Janaszewska A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805602
[TBL] [Abstract][Full Text] [Related]
32. The role of caveolin-1 and syndecan-4 in the internalization of PEGylated PAMAM dendrimer polyplexes into myoblast and hepatic cells.
Shen W; van Dongen MA; Han Y; Yu M; Li Y; Liu G; Banaszak Holl MM; Qi R
Eur J Pharm Biopharm; 2014 Nov; 88(3):658-63. PubMed ID: 25083608
[TBL] [Abstract][Full Text] [Related]
33. Effects of the surface charge of polyamidoamine dendrimers on cellular exocytosis and the exocytosis mechanism in multidrug-resistant breast cancer cells.
Zhang J; Li M; Wang M; Xu H; Wang Z; Li Y; Ding B; Gao J
J Nanobiotechnology; 2021 May; 19(1):135. PubMed ID: 33980270
[TBL] [Abstract][Full Text] [Related]
34. Application of biodegradable dendrigraft poly-l-lysine to a small interfering RNA delivery system.
Kodama Y; Kuramoto H; Mieda Y; Muro T; Nakagawa H; Kurosaki T; Sakaguchi M; Nakamura T; Kitahara T; Sasaki H
J Drug Target; 2017 Jan; 25(1):49-57. PubMed ID: 27125178
[TBL] [Abstract][Full Text] [Related]
35. Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model.
Bohr A; Tsapis N; Foged C; Andreana I; Yang M; Fattal E
Eur J Pharm Biopharm; 2020 Nov; 156():114-120. PubMed ID: 32798665
[TBL] [Abstract][Full Text] [Related]
36. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
[TBL] [Abstract][Full Text] [Related]
37. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action.
Dzmitruk V; Szulc A; Shcharbin D; Janaszewska A; Shcharbina N; Lazniewska J; Novopashina D; Buyanova M; Ionov M; Klajnert-Maculewicz B; Gómez-Ramirez R; Mignani S; Majoral JP; Muñoz-Fernández MA; Bryszewska M
Int J Pharm; 2015 May; 485(1-2):288-94. PubMed ID: 25796120
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of cationic dendrimer and lipid as transfection reagents of short RNAs for stem cell modification.
Ziraksaz Z; Nomani A; Soleimani M; Bakhshandeh B; Arefian E; Haririan I; Tabbakhian M
Int J Pharm; 2013 May; 448(1):231-8. PubMed ID: 23535347
[TBL] [Abstract][Full Text] [Related]
39. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
Kim B; Park JH; Sailor MJ
Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA).
Tsutsumi T; Hirayama F; Uekama K; Arima H
J Control Release; 2007 Jun; 119(3):349-59. PubMed ID: 17477999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
